Get the Stockscreener App
5.828
7.79%
0.438
Immix Biopharma Inc stock is traded at $5.828, with a volume of 602.26K.
It is up +7.79% in the last 24 hours and up +3.01% over the past month.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
See More
Previous Close:
$5.39
Open:
$5.4
24h Volume:
602.26K
Relative Volume:
0.60
Market Cap:
$308.73M
Revenue:
-
Net Income/Loss:
$-14.14M
P/E Ratio:
-6.3348
EPS:
-0.92
Net Cash Flow:
$-12.64M
1W Performance:
+26.30%
1M Performance:
+3.01%
6M Performance:
+114.38%
1Y Performance:
+202.12%
1-Day Range:
$5.40
$5.97
1-Week Range:
$4.5503
$5.97
52-Week Range:
$1.34
$7.73
Immix Biopharma Inc Stock (IMMX) Company Profile
Name
Immix Biopharma Inc
Sector
Industry
Phone
(888) 958-1084
Address
11400 WEST OLYMPIC BLVD., LOS ANGELES
Compare IMMX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
5.83 | 285.43M | 0 | -14.14M | -12.64M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.56 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.32 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
868.54 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
361.68 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.25 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Immix Biopharma Inc Stock (IMMX) Latest News
Market Recap: Why Immix Biopharma Inc. stock remains undervaluedQuarterly Market Summary & Comprehensive Market Scan Reports - bollywoodhelpline.com
Is Immix Biopharma Inc stock a good pick for beginnersMarket Trend Report & Safe Entry Point Identification - baoquankhu1.vn
Published on: 2026-01-13 06:33:30 - Улправда
Immix Biopharma (IMMX) Shares Slip As Investors Focus On Plans To Offer And Sell $750 Million In Securities - Benzinga
Immix Biopharma (NASDAQ:IMMX) Downgraded to Sell Rating by Wall Street Zen - Defense World
Immix Biopharma to offer and sell up to $750 million in securitiesSEC filing - marketscreener.com
Immix Biopharma — NXC-201’s path to BLA submission - Smartkarma
Why analysts upgrade Immix Biopharma Inc. stock2025 Winners & Losers & Low Risk High Win Rate Picks - ulpravda.ru
Why Immix Biopharma Inc. stock is a must watch in 2025July 2025 Decliners & High Accuracy Investment Entry Signals - Улправда
Why Immix Biopharma Inc. stock remains undervalued2025 Earnings Impact & High Return Trade Guides - Улправда
What technical charts say about Immix Biopharma Inc. stock2025 Support & Resistance & Weekly Watchlist for Hot Stocks - ulpravda.ru
What momentum indicators show for Immix Biopharma Inc. stockRate Hike & Accurate Intraday Trading Signals - ulpravda.ru
Fed Watch: Why analysts upgrade Immix Biopharma Inc stockWeekly Trading Summary & Risk Adjusted Swing Trade Ideas - Bộ Nội Vụ
Swing Trade: Can Immix Biopharma Inc stock surprise with earnings upsidePortfolio Update Report & Consistent Profit Alerts - moha.gov.vn
Why Immix Biopharma Inc stock remains undervaluedJuly 2025 Patterns & Fast Exit and Entry Trade Guides - moha.gov.vn
Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Up 27.5% in December - MarketBeat
Immix Biopharma (NASDAQ:IMMX) & Athira Pharma (NASDAQ:ATHA) Critical Survey - Defense World
Immix Biopharma (IMMX) price target increased by 50.00% to 12.24 - MSN
Immix Biopharma (IMMX) Price Target Increased by 50.00% to 12.24 - Nasdaq
Is Immix Biopharma Inc. stock resilient to inflation2025 Growth vs Value & Accurate Buy Signal Notifications - Улправда
Is Immix Biopharma Inc. stock positioned well for digital economyTake Profit & Expert Curated Trade Setups - Улправда
Why Immix Biopharma Inc. stock remains on buy listsPortfolio Return Report & Precise Swing Trade Entry Alerts - DonanımHaber
Is Immix Biopharma Inc. stock positioned for long term growth2025 Retail Activity & Free Risk Controlled Daily Trade Plans - DonanımHaber
What hedge fund activity signals for Immix Biopharma Inc. stock2025 Sector Review & Free Risk Controlled Daily Trade Plans - ulpravda.ru
Immix Biopharma (NASDAQ:IMMX) Stock Rating Upgraded by Wall Street Zen - Defense World
Immix Biopharma Inc Stock Analysis and ForecastGeopolitical Risk Analysis & Minimal Risk High Reward - earlytimes.in
Trendlines Converge — Decision Point for Tirupati Starch and Chemicals LimitedTake Profit Strategies & Compound Your Gains With Quality Stocks - earlytimes.in
Immix Biopharma FY2025 EPS Forecast Boosted by HC Wainwright - Defense World
Aug Summary: Will Immix Biopharma Inc stock benefit from infrastructure spending2025 Macro Impact & Verified Entry Point Detection - moha.gov.vn
FY2025 EPS Estimates for Immix Biopharma Lifted by Analyst - MarketBeat
Immix Biopharma: Thesis Playing Out; Thoughts On Valuation And Competition (IMMX) - Seeking Alpha
Immix Biopharma Stock Surges 70%, With A 6-Day Winning Spree - Trefis
Immix Biopharma CFO Gabriel Morris buys $5k in shares By Investing.com - Investing.com Canada
Ilya Rachman, Immix Biopharma CEO, buys $4975 in shares By Investing.com - Investing.com Canada
Immix Biopharma CFO Gabriel Morris buys $5k in shares - Investing.com
Ilya Rachman, Immix Biopharma CEO, buys $4975 in shares - Investing.com
Immix Biopharma stock price target raised to $12 from $8 at H.C. Wainwright - Investing.com Australia
Immix Biopharma stock price target raised to $12 from $8 at H.C. Wainwright By Investing.com - Investing.com South Africa
IMMX Analyst Rating Update: HC Wainwright Raises Price Target to - GuruFocus
Immix Biopharma closes $93.7 million public offering By Investing.com - Investing.com Canada
Immix Biopharma closes $93.7 million public offering - Investing.com
Immix Biopharma announces closing of upsized $100 million underwritten offering of common stock and pre-funded warrants - marketscreener.com
Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Immix Biopharma, Inc. Closes $93.7 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Immix Biopharma prices $100M equity raise via common stock and warrant offering - MSN
Immix Biopharma Inc Stock (IMMX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immix Biopharma Inc Stock (IMMX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Morris Gabriel S | CFO |
Dec 10 '25 |
Buy |
6.58 |
770 |
5,067 |
291,429 |
| Rachman Ilya M | CEO and Chairman |
Sep 17 '25 |
Buy |
2.02 |
2,500 |
5,050 |
1,140,937 |
| Morris Gabriel S | CFO |
Sep 16 '25 |
Buy |
1.97 |
2,600 |
5,122 |
290,659 |
| Rachman Ilya M | CEO and Chairman |
Jun 18 '25 |
Buy |
2.29 |
2,178 |
4,999 |
1,138,437 |
| Morris Gabriel S | CFO |
Jun 18 '25 |
Buy |
2.28 |
2,225 |
5,071 |
288,059 |
2.34%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):